Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

Published Date: 21 Jun 2024

High-rate of durable responses with ViPOR sparks talk of supplanting CAR-T in second line

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

2.

CAR T cells improve patients' quality of life: a study

3.

New policy review highlights the importance of health-related quality of life in advanced cancer

4.

EBV Screening Tied to Lower Nasopharyngeal Cancer Mortality Risk

5.

From sweetener to cancer fighter? Fermented stevia shows promise in pancreatic cancer study


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot